{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=KRAS%2C+NRAS%2C+HRAS-mutated+NSCLC",
    "query": {
      "condition": "KRAS, NRAS, HRAS-mutated NSCLC"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 4,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T06:48:53.955Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06162221",
      "title": "Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer, NSCLC",
        "KRAS, NRAS, HRAS-mutated NSCLC",
        "KRAS G12C-mutated Solid Tumors, Lung Cancer",
        "Lung Cancer Stage IV, Advanced Solid Tumor, Cancer",
        "RAS G12D-mutated NSCLC"
      ],
      "interventions": [
        {
          "name": "RMC-6291",
          "type": "DRUG"
        },
        {
          "name": "RMC-6236",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "RMC-9805",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Revolution Medicines, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 616,
      "start_date": "2024-01-18",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-03-09",
      "last_synced_at": "2026-05-22T06:48:53.955Z",
      "location_count": 26,
      "location_summary": "Gilbert, Arizona • Duarte, California • Irvine, California + 21 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06162221"
    },
    {
      "nct_id": "NCT06881784",
      "title": "Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "NSCLC (Non-small Cell Lung Cancer)",
        "Non-Small Cell Lung Cancer",
        "NSCLC",
        "NSCLC (Non-small Cell Lung Carcinoma)",
        "NSCLC (Advanced Non-small Cell Lung Cancer)"
      ],
      "interventions": [
        {
          "name": "daraxonrasib",
          "type": "DRUG"
        },
        {
          "name": "docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Revolution Medicines, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 420,
      "start_date": "2025-05-06",
      "completion_date": "2030-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-12",
      "last_synced_at": "2026-05-22T06:48:53.955Z",
      "location_count": 34,
      "location_summary": "Birmingham, Alabama • Long Beach, California • New Haven, Connecticut + 30 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Plantation",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06881784"
    },
    {
      "nct_id": "NCT04566393",
      "title": "Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies",
      "overall_status": "AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Pancreatic Cancer",
        "Small Bowel Cancer",
        "Colorectal Cancer",
        "Melanoma",
        "Non Small Cell Lung Cancer",
        "Thyroid Cancer",
        "Bladder Cancer",
        "Head and Neck Cancer",
        "Gastric Cancer",
        "Esophageal Cancer",
        "Cholangiocarcinoma",
        "Ovarian Cancer",
        "Hepatocellular Carcinoma",
        "Glioblastoma",
        "MAPK Gene Mutation",
        "KRAS Activating Mutation",
        "BRAF Gene Mutation",
        "NRAS Gene Mutation",
        "HRAS Gene Mutation",
        "MEK Mutation",
        "ERK Mutation"
      ],
      "interventions": [
        {
          "name": "Ulixertinib (BVD-523)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "xCures",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2026-01-28",
      "last_synced_at": "2026-05-22T06:48:53.955Z",
      "location_count": 27,
      "location_summary": "Huntsville, Alabama • Mobile, Alabama • Arroyo Grande, California + 20 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Arroyo Grande",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04566393"
    },
    {
      "nct_id": "NCT07397338",
      "title": "Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Metastatic Solid Tumors",
        "Non-small Cell Lung Cancer (NSCLC)",
        "NSCLC",
        "Colorectal Cancer (CRC)",
        "CRC"
      ],
      "interventions": [
        {
          "name": "Daraxonrasib",
          "type": "DRUG"
        },
        {
          "name": "Elironrasib",
          "type": "DRUG"
        },
        {
          "name": "Zoldonrasib",
          "type": "DRUG"
        },
        {
          "name": "Ivonescimab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only)",
          "type": "DRUG"
        },
        {
          "name": "cetuximab (Cohort C2 Only)",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only)",
          "type": "DRUG"
        },
        {
          "name": "Daraxonrasib (Cohort B1 only)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Revolution Medicines, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 370,
      "start_date": "2026-01-30",
      "completion_date": "2029-05",
      "has_results": false,
      "last_update_posted_date": "2026-05-12",
      "last_synced_at": "2026-05-22T06:48:53.955Z",
      "location_count": 5,
      "location_summary": "Norwich, Connecticut • Nashville, Tennessee • Irving, Texas + 2 more",
      "locations": [
        {
          "city": "Norwich",
          "state": "Connecticut"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Irving",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07397338"
    }
  ]
}